|
|
Volumn 49 Suppl A, Issue , 2001, Pages
|
|
Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETAMIDE DERIVATIVE;
ANTIINFECTIVE AGENT;
LINEZOLID;
OXAZOLIDINONE DERIVATIVE;
ANTIBIOTIC RESISTANCE;
ARTICLE;
BACTERIAL INFECTION;
CHEMISTRY;
COST BENEFIT ANALYSIS;
CROSS INFECTION;
ECONOMICS;
HUMAN;
INFECTION CONTROL;
PENICILLIN RESISTANCE;
PRACTICE GUIDELINE;
PUBLICATION;
STANDARD;
STAPHYLOCOCCUS AUREUS;
UNITED STATES;
ACETAMIDES;
ANTI-BACTERIAL AGENTS;
CHEMISTRY, PHARMACEUTICAL;
COST-BENEFIT ANALYSIS;
CROSS INFECTION;
DRUG RESISTANCE, BACTERIAL;
FORMULARIES, HOSPITAL;
GRAM-POSITIVE BACTERIAL INFECTIONS;
HUMANS;
INFECTION CONTROL;
METHICILLIN RESISTANCE;
OXAZOLIDINONES;
PRACTICE GUIDELINES;
STAPHYLOCOCCUS AUREUS;
UNITED STATES;
MLCS;
MLOWN;
|
|
EID: 0035752837
PISSN: 01956701
EISSN: None
Source Type: Journal
DOI: 10.1016/s0195-6701(01)90032-5 Document Type: Article |
|
Times cited : (13)
|
|
References (0)
|
